Key highlights
- Andromeda Metals (ASX:ADN) closed at A$0.006 on 12 November 2026, up 10.00% on the session.
- Independent Eurofins analysis confirmed high-purity alumina (HPA) purity of up to 99.9989% from pilot plant samples.
- The company's first commercial HPA sample was sent to a potential customer in Japan, with more samples expected through Q4 2026.
Andromeda Metals (ASX:ADN) shares closed at A$0.006 on 12 November 2026, up 10.00% on the session. The S&P/ASX 200 fell 0.71% to 9,082.20, while the S&P/ASX 200 Materials index slid 1.61% to 22,911.10. Andromeda is an Australian company developing its Great White kaolin resource and a patented process to produce high-purity alumina for technology markets. Its latest update, released on 29 October 2026, reported pilot plant HPA purity of up to 99.9989% and the dispatch of its first commercial sample to Japan for customer evaluation.
Pilot Plant Purity Confirmed by Eurofins
On 29 October 2026, Andromeda reported that independent analysis by EAG Eurofins of three samples from its continuous pilot plant confirmed HPA purity of up to 99.9989%. Two of the three samples recorded that level, while the third measured 99.9986%. Using glow discharge mass spectrometry, Eurofins reported total metallic impurities as low as 10.84 ppm. A more conservative calculation that includes reporting limits produced purity of up to 99.9966%, and the company said both methods confirm production of 4N high-purity alumina above 99.99% Al2O3.
First Commercial Sample Sent to Japan
Andromeda also said the inaugural commercial sample had been dispatched to Japan for evaluation by a potential customer in the high-tech Manufacturing sector. Further samples are expected to be sent throughout the remainder of Q4 2026 as part of its customer engagement program. Acting chief executive Sarah Clarke said sustained pilot-scale production and the start of customer evaluations were an important step in the commercialisation strategy. The company linked the program to a strategic HPA Supply Heads of Agreement with Traxys North America, announced on 19 August 2026, which provides a pathway for customer engagement in the United States.
Pilot Program and Pre-Feasibility Planning
The pilot plant is designed to produce samples for customer qualification, refine the process flowsheet, assess operating parameters and generate engineering data. Andromeda has confirmed that commissioning and first HPA production are complete, while customer sample availability has commenced. Work is also under way to assess amorphous silica, a by-product of the process. The pilot data is feeding into the planned Pre-Feasibility Study, for which planning is underway. Andromeda was granted its first Patent for the proprietary process on 6 October 2026, and its 2025 scoping study assessed staged development of up to 10,000 tonnes per annum with a pre-tax NPV10 of approximately A$1.48 billion.
Sector Context
High-purity alumina is used in batteries, semiconductors, LEDs, synthetic sapphire and advanced ceramics, which ties Demand to electronics and energy storage. Few ASX producers supply the material at commercial scale, so the sector remains at an early stage. On 12 November the broader resources sector was under pressure, with the Materials index down 1.61%, which puts Andromeda's gain against a weaker backdrop. The company's scoping study indicated it could be a low operating cost HPA producer, but that comparison depends on pilot results holding up at larger scale.
Risks Investors Are Watching
Commercial samples are still under evaluation, and no customer qualification or supply agreement has been announced. Pilot-scale results do not guarantee commercial production outcomes, and Andromeda has said results are being compared with the assumptions in its scoping study. The Pre-Feasibility Study is still in planning, and the company's forward-looking statements carry standard uncertainties around timing, costs and outcomes. The value of the amorphous silica by-product has not yet been established.
What to Watch Ahead
Attention will turn to the further commercial samples due through Q4 2026 and to any feedback from customers, which the company says will inform product optimisation and market selection. Progress on the Pre-Feasibility Study, the results of silica characterisation work and any update on the Traxys arrangement for US supply will also be closely followed.
Final Word
Andromeda's 12 November gain came on a day when the wider market and the materials sector both retreated. Its recent updates have centred on purity results and early customer evaluation, and the next phase will be measured by the feedback from those samples.

_11_18_2026_02_14_42_047213.jpg)




Please wait processing your request...